Table 2.

The relationship between prognostic factors and progression-free survival or overall survival in patients with non-small-cell lung cancer receiving first-line pembrolizumab monotherapy: univariate and multivariate Cox-regression analysis

	Progression-free survival				Overall survival
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age, years (≤64, 65-74, ≥75)	0.73 (0.57-0.93)	0.011			0.82 (0.63-1.06)	0.815
Sex (male, female)	1.02 (0.75-1.39)	0.901			1.08 (0.77-1.50)	0.670
Performance status (0, 1, 2)	1.71 (1.28-2.27)	<0.001	1.48 (1.11-1.98)	0.019	1.87 (1.37-2.55)	<0.001	1.48 (1.06-2.06)	0.021
Histological subtype (squamous, non-squamous)	1.06 (0.73-1.54)	0.767			1.17 (0.91-1.50)	0.229
WCC (≤11 × 109/l, >11 × 109/l)	1.92 (1.40-2.63)	<0.001			2.21 (1.58-3.09)	<0.001
Neutrophils (≤7.5 × 109/l, >7.5 × 109/l)	2.47 (1.80-3.38)	<0.001	1.73 (1.22-2.44)	0.002	2.92 (2.07-4.11)	<0.001	2.10 (1.48-3.03)	<0.001
Neutrophil/lymphocyte ratio (≤5, >5)	2.03 (1.49-2.78)	<0.001			2.39 (1.70-3.36)	<0.001
Platelet/neutrophil ratio (≤180, >180)	1.44 (1.00-2.07)	0.052			1.55 (1.04-2.32)	0.031
Albumin (<35 g/l, ≥35 g/l)	2.56 (1.84-3.58)	<0.001	2.11 (1.48-3.00)	<0.001	3.06 (2.11-4.44)	<0.001	2.29 (1.55-3.39)	<0.001
Prognostic nutritional index (<45, ≥45)	1.87 (1.30-2.69)	0.001			2.70 (1.75-4.17)	<0.001

Bold and italic values are statistically significant.

CI, confidence interval; HR, hazard ratio; WCC, white cell count.